P1101

Phase 2Small molecule

PPharmaEssentia Japan K.K.

P1101 is one of 63 small molecule programs targeting Polycythemia Vera. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycythemia VeraActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Polycythemia VeraPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Sovaldi

Gilead

Preclinical

1 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Coreg

Akero Therapeutics

Preclinical

2 5

P1101

PPharmaEssentia Japan K.K.

Phase 2

1 6

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 7

Opdivo

Bristol-Myers Squibb

Preclinical

2 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Efficacy

NCT05481151

Clinical

Trials by Indication[1]

Treatment1 trial

Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 1·NCT01933906·12 enrolled

Polycythemia Vera1 trial

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Completed·PPharmaEssentia Japan K.K.·Phase 2·NCT04182100·29 enrolled

Hepatocellular Carcinoma1 trial

P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma

Unknown status·NNational Taiwan University Hospital·Phase 1/2·NCT04233840·72 enrolled

Efficacy and Safety1 trial

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.

Completed·NNational Taiwan University Hospital·Phase 3·NCT05770466·134 enrolled

Efficacy1 trial

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Active, not recruiting·PPharmaEssentia·Phase 3·NCT05481151·111 enrolled

3 more indications

Phase 21 trial

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Recruiting·PPharmaEssentia Japan K.K.·Phase 3·NCT04655092·67 enrolled

Single Dose1 trial

Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects

Completed·PPharmaEssentia·Phase 1·NCT05129644·48 enrolled

Unspecified1 trial

A Study to Evaluate P1101 in Japanese PV Patients

Completed·PPharmaEssentia Japan K.K.·Phase 3·NCT06002490·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for P1101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — P1101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for P1101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PharmaEssentia Japan K.K. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPharmaEssentia Japan K.K.

P1101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Treatment1 trial

Polycythemia Vera1 trial

Hepatocellular Carcinoma1 trial

Efficacy and Safety1 trial

Efficacy1 trial

Phase 21 trial

Single Dose1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News